Researchers have reported that the predictive abilities of a machine learning algorithm trained using best practices on a large clinical dataset did not generalize beyond the data that was used to train it. The algorithm was able to predict, to a degree, which individual patients would benefit from the medication when the patients were from the dataset the algorithm was trained on. But when it was supposed to predict who would benefit in clinical cohorts that were not part of the training, it performed no better than chance. Read More
Researchers from China have elucidated the prognostic role of aberrant expression of RNA binding motif protein, X chromosome (RBMX) in several cancer types using samples from cancer patients. Read More
Angiopoietin-like 4 (ANGPTL4) is a glycosylated and secreted protein that functions as a regulator of cell metabolism and angiogenesis, and which has been shown to play a critical role in tumorigenesis. Read More
The combination of chemotherapy (CT) and photodynamic therapy (PDT), which combines light and a photosensitizing agents, is increasingly being used to enhance the efficacy of cancer treatments. Read More
Researchers at University of Arizona and University of Dundee have disclosed dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes, osteoarthritis, Down syndrome, inflammatory disorder, autoimmune and Alzheimer’s disease. Read More
Inhibiting the aggregation process of Aβ42 is one of the main objectives in the development of therapies for Alzheimer’s disease, but the heterogeneous nature of the neurotoxic oligomers poses a significant challenge. Researchers from the Universita degli Studi di Firenze presented the preclinical evaluation of DesAb-O, a single-domain antibody targeting Aβ42 oligomers. Read More
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has synthesized molecular glue compounds targeting protein cereblon (CRBN) acting as CRBN/target protein interaction inducers reported to be useful for the treatment of cancer. Read More
Diabetic sensory neuropathy (DSN) is among the most common complications of type 2 diabetes, but the mechanisms behind its pathogenesis are not clear. Read More
Tr1x Inc. announced a $75 million series A financing to advance universal allogeneic regulatory T (Treg) and chimeric antigen receptor (CAR)-Treg cell therapies into the clinic to treat autoimmune and inflammatory diseases. Read More
Cincinnati Children’s Hospital Medical Center has identified IL-1 receptor-associated kinase (IRAK) and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders. Read More
DNA replication stress induced by oncogenes is a known driver of chromosomal instability, which is associated with poor prognosis in several cancer types. Read More
Chulalongkorn University has divulged programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) modulators reported to be useful for the treatment of cancer. Read More
Mainline Biosciences (Shanghai) Co. Ltd. has described peptides acting as tachykinin NK1 receptor antagonists reported to be useful for the treatment of pain and opioid dependence. Read More
PDC*line Pharma SA has announced the selection of the PDC*neo+ project for funding by the Walloon region of Belgium and Biowin, the health cluster for Wallonia. Read More
Bolden Therapeutics Inc. has closed a $1.5 million pre-seed convertible note financing. This financing, together with National Institutes of Health (NIH) small business grants, will support preclinical development of Bolden's antisense oligonucleotides to promote neurogenesis. Read More
